Everolimus with low‐dose tacrolimus in simultaneous pancreas and kidney transplantation
- 1 June 2014
- journal article
- clinical trial
- Published by Wiley in Clinical Transplantation
- Vol. 28 (7) , 797-801
Abstract
The efficacy and safety of everolimus (EVR) in simultaneous pancreas and kidney transplantation (SPKT) is unclear. We retrospectively evaluated 25 consecutive SPKT recipients at our center from November 2011 to March 2013. All patients received dual induction (Thymoglobulin/basiliximab) and low‐dose tacrolimus plus corticosteroids. Nine patients who received EVR were compared with 14 patients who received enteric‐coated mycophenolate sodium (EC‐MPS); two patients who received sirolimus were excluded from the analysis. With a median follow‐up of 14 months, the pancreas graft survival rate was 100% in both groups, and the kidney graft survival rate was 100% and 93% in EVR and EC‐MPS patients, respectively. One EC‐MPS patient lost her kidney graft from proteinuric kidney disease. Another EC‐MPS patient received treatment for clinically diagnosed pancreas and kidney graft rejection. No rejection was observed in EVR patients. Serum creatinine and HbA1c levels were similar between the groups. There was no significant difference of surgical or medical complications. In conclusion, EVR seems to provide comparable short‐term outcome to EC‐MPS when combined with low‐dose tacrolimus/steroids and dual induction therapy. A larger study with a longer follow‐up is required to further assess this combination.Keywords
This publication has 23 references indexed in Scilit:
- Treatment with everolimus is associated with a procoagulant stateThrombosis Research, 2013
- Renal Function at Two Years in Liver Transplant Patients Receiving Everolimus: Results of a Randomized, Multicenter StudyAmerican Journal of Transplantation, 2013
- OPTN/SRTR 2011 Annual Data Report: PancreasAmerican Journal of Transplantation, 2012
- Impact of Tacrolimus-Sirolimus Maintenance Immunosuppression on Proteinuria and Kidney Function in Pancreas Transplant Alone RecipientsTransplantation, 2012
- Advantage of Rapamycin Over Mycophenolate Mofetil When Used With Tacrolimus for Simultaneous Pancreas Kidney Transplants: Randomized, Single-Center Trial at 10 YearsAmerican Journal of Transplantation, 2012
- Addition of anti‐CD25 to thymoglobulin for induction therapy: delayed return of peripheral blood CD25‐positive populationClinical Transplantation, 2010
- Similar Early Complication Rate in Simultaneous Pancreas and Kidney Recipients on Tacrolimus/Mycophenolate Mofetil Versus Tacrolimus/Sirolimus Immunosuppressive RegimensTransplantation Proceedings, 2010
- One Year Follow-up of Steroid-Free Immunosuppression Plus Everolimus in Isolated Pancreas TransplantationTransplantation, 2008
- Long-Term Renal Transplant Function in Recipient of Simultaneous Kidney and Pancreas Transplant Maintained With Two Prednisone-Free Maintenance Immunosuppressive Combinations: Tacrolimus/Mycophenolate Mofetil Versus Tacrolimus/SirolimusTransplantation, 2007
- Hypercoagulable state associated with kidney–pancreas transplantation. Thromboelastogram‐directed anti‐coagulation and implications for future therapyClinical Transplantation, 2004